Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of liposomal irinotecan combination versus nab-paclitaxel + gemcitabine in untreated metastatic pancreatic adenocarcinoma
MOH_2020-08-24_009254Phase 3Not yet recruiting
- Sponsor
- Ipsen
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (2 arms), sponsored by Ipsen. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on MOH_2020-08-24_009254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-24_009254.